Elucida Oncology
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (NCT05622591) | Elucida Oncology | 2024-06-07 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
Track Elucida Oncology automatically
Every clearance here is in the API, with alerts when new ones post.